Medical network - on August 21, according to the voice of the economy, the world of finance and economics newspaper shortage of medicine is to point to in a certain area can't normal supply of drugs, reporter survey found that the phenomenon of shortage of medicine rises in price considerably is more and more, the price of some drugs can rise several times in a short time. There is some evidence that some of the price increases are being manipulated.
Price hike: not a drug agent, but an upstream enterprise?
In the interview, the drugstore told reporters that the price of the shortage was not related to them. Some hospitals have judged that it is unlikely that drug dealers will raise prices.
"I think it's very unlikely that the middlemen will go up so much," said the head of a hospital's drug purchasing department, "because it has gone up so far."
The head of a pharmaceutical company says many of the price rises stem from upstream companies, producers and agents of API. He told reporters that the agent who had the API had made unreasonable demands on himself. He said: "because last year I gave the raw materials to the manufacturers, and now I have not sent the raw materials to me. He asked for that, for example, that you gave me all the preparation, and I said why I gave it to you. Then the raw material manufacturer he did not say dead hair does not send, say you try to negotiate. Then I said I couldn't negotiate, or you'd get a refund and I wouldn't do it. "
Control drug production upstream and downstream, raise the price
The pharmaceutical companies, officials say, API agent is the purpose of recycling drugs to control drug, so you can "one-stop" to control the upstream and downstream of drug production, and higher drug prices.
Reporter verification to the national development and reform commission, the national development and reform commission, the anti-monopoly bureau of investigation two everywhere long xin-yu xu said, there is a similar phenomenon, a shortage of medicine market in the field of antitrust, this is called abuse of dominant market position.
"For example, if there are only two factories," xu said, "he would find a factory, which was a thousand dollars a ton, and now he is buying it for 10,000 yuan." After the purchase, that is to say I am to appoint you to which preparation factory you sell to which preparation factory, then is the preparation factory controls upstream and downstream linkage, that price comes up."
On August 15th, the national development and reform commission has announced the administrative penalty, new secco pharmaceutical industry of zhejiang and tianjin han, pharmaceutical industry, why is the two companies abuse of isoniazid API dominant market position, the implementation of price monopoly. The reason why the price of isoniazid rose more than 20 times in the short term is also revealed.
Surprised! Individuals can control a drug
Drug price monopoly has one characteristic, that is to give priority to with small and medium enterprises, some even individual can control a kind of medicine.
Xu xinyu told the reporter: "he is an attending physician at a famous three-level hospital in Beijing. He quit his job. He raised tens of millions to control a small medicine for heart disease, which he thought was an investment. He began to understand, and we talked to him about it, and he didn't do it. "
It is understood that the price monopoly has the vertical monopoly of upstream and downstream enterprises and the horizontal monopoly of similar enterprises. The previous price increase of the other drug has been colluded by several pharmaceutical companies. The vice President of China university of political science and law said that as the price regulator intensified its crackdown, there was an increasingly covert trend in the price monopoly of drug shortages.
"In the sense of the anti-monopoly law, he might have called a phone, said I would raise the price tomorrow, and said I knew what you meant," he said. But after they got in touch, the price really went up.
|
